Epitalon, MOTS-c, NAD+ and SS-31: longevity promise vs. proof

Key points

• Epitalon’s reputation comes from cell-culture studies. In 2025 an independent study found it also lengthened telomeres in breast-cancer cells [1][2].
• MOTS-c has mouse data. There are no published human efficacy trials, and the first registered one (phase 2a) is recruiting [3][4][12].
• A 2026 review found no clinical-outcome trials of intravenous or intramuscular NAD+ [5].
• SS-31 (elamipretide) received FDA accelerated approval in 2025, for Barth syndrome only [7].

US status (October 2026): Epitalon and MOTS-c are not FDA-approved and have no lawful compounding pathway, NAD sits in 503A Category 1 for patient-specific compounding, and elamipretide is approved only as Forzinity for Barth syndrome. See the epitalon, MOTS-c and NAD+ status pages.

None of these four compounds has human evidence that it slows aging. One has a narrow approval for an ultra-rare disease. The rest sit on cell, mouse and biomarker data. That is what you tell a patient who asks for a longevity stack.

Longevity interest has reached the FDA agenda

Longevity became a market, and peptides became its flagship product. In July 2026 FDA’s Pharmacy Compounding Advisory Committee put MOTS-c and epitalon on its agenda alongside BPC-157, TB-500 and others [9]. The core question is unchanged: is there human evidence that any of them slows aging. As of October 2026, the answer is no.

Epitalon’s telomere data come from cell culture

Epitalon (AEDG) is a tetrapeptide. Its reputation comes from a 2003 study in cultured human fetal fibroblasts, where it was associated with telomerase activation and telomere lengthening [1]. Much of the later literature comes from the same St. Petersburg group.

In 2025 an independent study confirmed telomere lengthening in normal cells, via telomerase. It also found something uncomfortable: in breast-cancer cell lines, telomeres lengthened too, through a different mechanism (ALT) [2]. We found no independent controlled trials measuring clinical outcomes.

MOTS-c has mouse data and one recruiting trial

MOTS-c is a peptide encoded in mitochondrial DNA. In mice it was associated with preventing diet- and age-related insulin resistance [3] and with better physical capacity [4]. In humans, exercise has been shown to raise the body’s own MOTS-c [4]. That is no evidence that injecting it has an effect. We found no published human efficacy trials. The first registered randomized trial, a phase 2a study in adults with prediabetes and overweight or obesity, was recruiting as of October 2026 [12].

• 0: clinical-outcome trials of IV or IM NAD+ [5]
• 33: human studies reviewed on NAD+ and precursors [5]
• 1: accelerated approval for SS-31, Barth syndrome only [7]

NAD+ rises in the blood, and the outcomes are mostly null

A 2026 systematic review examined 33 human intervention studies. Oral precursors (NR, NMN) do raise NAD metabolites. Effects on function and health were “heterogeneous and often null or endpoint-specific.” The review found no outcome trials of intravenous or intramuscular NAD+ for anti-aging or wellness [5]. In adults over 60, NMN and NR did not preserve muscle mass or function [6].

If you run an IV program, that gap shapes what you may say. Our post on NAD+ IV therapy claims covers the marketing side.

SS-31’s approval is narrow and does not cover longevity

SS-31, or elamipretide, is the only one in this group with a regulatory approval. On September 19, 2025 FDA granted accelerated approval to Forzinity for Barth syndrome, an ultra-rare mitochondrial disease, in patients weighing at least 30 kg. It was based on improved knee-extensor strength as a surrogate endpoint and requires a confirmatory trial [7]. In the open-label extension of the TAZPOWER study, 8 of 10 patients reached week 168, with +96.1 m on the 6-minute walk [8].

What the approval does not mean. SS-31’s approval is narrow (one rare disease), provisional (accelerated) and specific. It does not validate its use for longevity [7].

The supporters’ case

The biology behind these compounds is serious: telomerase [1][2], mitochondrial signaling [3][4] and NAD metabolism [5]. SS-31 has already reached an approval [7]. In July 2026 the FDA advisory committee voted to recommend adding MOTS-c (7 to 5, two abstentions) [10] and epitalon, the latter for insomnia [11], to the 503A compounding list. Those votes are nonbinding, and FDA had not acted as of late September 2026, according to our status tracker. For supporters, longevity research is at an early stage, and early is different from failed.

For a clinic, the practical line is the regulatory one. Compounds with no pathway are often sold as research-use-only peptides, which are not lawful for patient use. The peptide status tracker shows where each one stands.

References

1. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-2. PMID 12937682. Link
2. Al-Dulaimi S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. PMID 40908429. Link
3. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54. PMID 25738459. Link
4. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID 33473109. Link
5. Gallagher C, et al. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. 2026;116:103057. PMID 41655607. Link
6. Prokopidis K, et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2025;16(3):e13799. PMID 40275690. Link
7. U.S. Food and Drug Administration. FDA grants accelerated approval to first treatment for Barth syndrome. 19 September 2025. Link
8. Thompson WR, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024;26(7):101138. PMID 38602181. Link
9. American Med Spa Association. FDA Advisory Committee Recommends Adding BPC-157 to Compounding List. 23 July 2026. Link
10. Jacobus N. FDA Panel Votes to Loosen Restrictions for Four Peptides. Pharmaceutical Executive. 24 July 2026. Link
11. Regulatory Focus (RAPS). FDA advisory committee backs two more peptides, rejects one for compounding list. July 2026. Link
12. ClinicalTrials.gov. NCT07505745: A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c in Adults With Prediabetes and Overweight/Obesity (recruiting). Accessed 9 October 2026. Link

This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.